Results
55 participants were screened during the initial phase of the study, and 40 were enrolled. Following the preliminary analysis of this initial phase, Groups 1 and 2 induced the highest immunogenic responses (highest anti-RBD IgG). An additional 26 participants were screened, and 20 subsequently enrolled in these two groups for the extended phase of this study. This amounted to a total of 60 participants enrolled in the study, with 3 excluded from its analysis due to positive baseline anti-NP or anti-RBD IgG antibody values (see Consort diagram. 55 participants were assessed for eligibility in the initial phase, and 40 were included and randomized (1:1:1:1) to receive accelerated intradermal regimens in the study. An additional 26 participants were assessed for eligibility in the extended phase, and 20 were included and randomized (1:1) into two of the four accelerated intradermal vaccine regimens. Participants were assessed thereafter at baseline (n = 57), 1 week after the first dose (n = 57), 2 weeks after the second dose (n = 55), and 12 weeks after the second dose (n =30).Baseline characteristics of the participants receiving accelerated regimens of intradermal COVID-19 vaccinations.Chi-square and Kruskal-Wallis tests were used to determine p-value among those who received any of the four vaccination regimens. ID, Intradermal.